Plain-English translation of NCT04151082 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether or — both steroid medications — can help reduce symptoms of nerve damage that some people develop years after radiation treatment for throat cancer. Specifically, it targets damage to lower nerves in the head and neck that can cause swallowing, voice, and tongue weakness. Researchers want to find the right dose of steroids that works best while being safe.
Some throat cancer survivors develop serious nerve damage months or years after their radiation therapy finishes, even when the cancer is gone. This can affect swallowing, voice, and tongue strength, hurting quality of life. There is currently no proven treatment, so this study is testing whether this medication can help recover some of that lost function.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive high-dose steroid medication — either as a daily oral pill (or through a feeding tube) or as an intravenous infusion — for 5 days, then gradually taper off over 2 weeks. You'll need to return for follow-up assessments after treatment to complete symptom surveys, physical exams, and possibly imaging or nerve tests. The study will track how your symptoms change and how well you function after the treatment.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States